Regulatory Strategy as a Development Accelerator: How to Compress Clinical Trial Timelines in India

In Pharmaceutical development, time is capital. Every month of delay between trial design and first patient enrolled has a quantifiable cost – in direct operational expenditure, in foregone revenue from delayed commercialisation, and in the opportunity cost of development resources committed to a delayed programme.

The sponsors who consistently achieve the fastest time from CTA submission to first patient enrolled in India are those who invest most heavily in regulatory strategy before the submission is filed – not those who spend the most on site management after approval.

1. Where Delays Actually Occur

1. Poor submission quality triggering CDSCO queries: A single query round adds 60–90 days. Multiple rounds – common for unadapted global dossiers – can extend the process by 6 months or more.
2. Sequential workstream management: Ethics committee review, site qualification, import licence preparation, and IP supply planning are frequently initiated only after CDSCO approval, adding 3–6 months that could have been parallelised.
3. Site selection delays: Sites chosen on relationship or convenience rather than systematic capability assessment lead to activation delays and enrolment shortfalls.
4. Import licence and IP supply chain: CT-16 (import of drugs for clinical trials) preparation started only after CTA approval adds 4–8 avoidable weeks.

2. The Regulatory Strategy Framework

Pre-Submission Regulatory Review (8–12 Weeks before submission): Define the optimal regulatory pathway; identify all India-specific protocol adaptations; complete the document checklist against CDSCO’s current requirements; define EC selection strategy and IP import pathway; set a milestone-driven project plan.

Parallel Ethics Committee Engagement: EC submission should be initiated simultaneously with CDSCO dossier preparation – not sequentially. Accredited ECs typically require 6–10 weeks for review. Parallel submission saves this entire period from the post-CDSCO approval critical path.

IP Import Licence Planning: CT-16 applications should be pre-prepared and ready for submission immediately upon CDSCO CTA approval which significantly reduces the timeline to 4-6 weeks.

Site Pre-Qualification During Regulatory Review: Conduct site selection visits and pre-qualification during the CDSCO review period so sites are fully qualified and ready for activation immediately upon approval.

Query Response Team on Standby: For complex submissions, identify and brief the query response team before submission. A pre-briefed team responds 30–50% faster than one assembled reactively after query receipt.

3. Timeline Comparison: Reactive vs. Strategic

The commercial and timeline impact of proactive regulatory strategy:

Table 1

The 4–10-month timeline difference is not theoretical. For a Drug with post-launch annual revenue potential of USD 50 million, a six-month acceleration has a net present value impact of approximately USD 15–25 million – against which expert Regulatory strategy investment is a fraction.

4. Specific Accelerators for 2026

SRA Expedited Pathway: For Drugs already approved by USFDA, EMA, or other SRA authorities, CDSCO’s 30-day review pathway provides significant acceleration. Confirm eligibility and structure the submission accordingly.

Pre-Submission Interaction with CDSCO: For novel trial designs or complex manufacturing situations, a pre-submission interaction can prevent the most consequential queries before the formal CTA is filed.

Adaptive Trial Design Considerations: CDSCO has expressed progressive interest in adaptive trial designs. Early regulatory engagement to confirm CDSCO’s expectations avoids mid-trial regulatory complications.

Conclusion

Clinical Trial timeline in India is a regulatory strategy problem before it is an operational one. The investment required for a comprehensive regulatory strategy framework is modest relative to total programme cost. The timeline and cost impact of not having one is not.

CliniExperts Research provides regulatory strategy, CTA preparation, and Clinical Trial management designed to maximise timeline efficiency in India.

About CliniExperts

CliniExperts Services Pvt. Ltd. and CliniExperts Research Pvt. Ltd. are part of the CE Group, a leading healthcare regulatory consulting and CRO group headquartered in Bengaluru and New Delhi, India. Our client portfolio includes over 300 companies across 40+ countries.

www.cliniexperts.com  |  contact@cliniexperts.com